Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today)

Amgen Confirms GDNF Halt In Parkinson's Development

Feb. 14, 2005

By Jennifer Boggs

Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...